COVID-19患者的血栓栓塞风险与抗凝治疗:新证据与行动呼吁
新证据显示重症COVID-19可并发凝血病,呈促血栓倾向且静脉血栓栓塞风险高。D-二聚体有助于早期识别高危患者并预测结局。初步数据显示抗凝治疗在符合脓毒症诱导凝血病标准或D-二聚体显著升高的亚组中与较低死亡率相关。近期建议所有住院COVID-19患者应接受血栓预防,有指征时行全治疗强度抗凝。
要点
- 重症COVID-19可并发促血栓性凝血病,静脉血栓栓塞风险高。
- D-二聚体有助于早期识别高危患者并预测结局。
- 抗凝在脓毒症诱导凝血病或D-二聚体显著升高者中与较低死亡率相关。
核心结论
- 重症COVID-19可并发以促血栓为特征的凝血病,静脉血栓栓塞风险高。
- 抗凝治疗在特定亚组中与较低死亡率相关,所有住院患者建议血栓预防。
主要发现
- ICU中COVID-19患者的静脉血栓栓塞发生率似高于其他疾病同类患者。
- D-二聚体可能有助于早期识别高危患者并预测结局。
- 初步数据显示抗凝治疗在符合脓毒症诱导凝血病标准或D-二聚体显著升高的重症患者中与较低死亡率相关。
关键数值与推荐
- 所有住院COVID-19患者应接受血栓预防。
- 存在指征时应给予全治疗强度抗凝。
临床怎么用
- 对所有住院COVID-19患者进行血栓预防。
- 有抗凝指征时采用全治疗强度抗凝。
- 用D-二聚体辅助识别高危患者并预测结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in intensive care units appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.
引用
- Kollias A, Kyriakoulis KG, Dimakakos E, et al. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020. PMID: 32304577. doi:10.1111/bjh.16727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。